These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3136608)

  • 1. Tolerability and immunogenicity of a polyvalent Pseudomonas aeruginosa extract vaccine in human volunteers.
    Martindale JJ; Ganzinger U; Steinmüller W; Millendorfer A; Ambrosch F; Kollaritsch H; Wiedermann G
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 May; 268(3):376-85. PubMed ID: 3136608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine.
    Barclay GR; Yap PL; McClelland DB; Jones RJ; Roe EA; McCann MC; Micklem LR; James K
    J Med Microbiol; 1986 Feb; 21(1):87-90. PubMed ID: 3081727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of immunisation with Pseudomonas aeruginosa on gut-derived sepsis in mice.
    Matsumoto T; Tateda K; Miyazaki S; Furuya N; Ohno A; Ishii Y; Hirakata Y; Yamaguchi K
    J Med Microbiol; 1998 Apr; 47(4):295-301. PubMed ID: 9568994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinico-immunological trials of Pseudomonas aeruginosa vaccine.
    Stanislavsky ES; Balayan SS; Sergienko AI; Makarenko TA; Edvabnaya LS; Krohina MA; Rusanov VM
    Vaccine; 1991 Jul; 9(7):491-4. PubMed ID: 1910233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of type specific IgG Pseudomonas antibodies by the ELISA test after administration of the anti Pseudomonas aeruginosa vaccine.
    Meitert T; Meitert E; Pencu E; Tonciu M
    Arch Roum Pathol Exp Microbiol; 1984; 43(1):53-60. PubMed ID: 6442132
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.
    Jones RJ
    J Hyg (Lond); 1979 Jun; 82(3):453-62. PubMed ID: 109501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Ttitova TI; Grigor'ev NI; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis.
    Döring G; Dorner F
    Behring Inst Mitt; 1997 Feb; (98):338-44. PubMed ID: 9382758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
    Cryz SJ; Sadoff JC; Cross AS; Fürer E
    Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzyme-linked immunosorbent assay (ELISA) and a passive haemagglutination test (PHT) for the detection of pseudomonas antibodies in burned patients.
    Roe EA; Jones RJ
    Burns Incl Therm Inj; 1985 Apr; 11(4):252-8. PubMed ID: 3924353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine.
    Hosea SW; Burch CG; Brown EJ; Berg RA; Frank MM
    Lancet; 1981 Apr; 1(8224):804-7. PubMed ID: 6111673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.
    Bruderer U; Cryz SJ; Schaad UB; Deusinger M; Que JU; Lang AB
    J Infect Dis; 1992 Aug; 166(2):344-9. PubMed ID: 1634805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.
    Cripps AW; Peek K; Dunkley M; Vento K; Marjason JK; McIntyre ME; Sizer P; Croft D; Sedlak-Weinstein L
    Infect Immun; 2006 Feb; 74(2):968-74. PubMed ID: 16428742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule.
    Booy R; Taylor SA; Dobson SR; Isaacs D; Sleight G; Aitken S; Griffiths H; Chapel H; Mayon-White RT; Macfarlane JA
    Arch Dis Child; 1992 Apr; 67(4):475-8. PubMed ID: 1580674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
    Cryz SJ; Sadoff JC; Fürer E; Germanier R
    J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients.
    Kim DK; Kim JJ; Kim JH; Woo YM; Kim S; Yoon DW; Choi CS; Kim I; Park WJ; Lee N; Jung SB; Ahn BY; Nam SW; Yoon SM; Choi WJ
    Vaccine; 2000 Dec; 19(9-10):1274-83. PubMed ID: 11137267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new Pseudomonas vaccine: preliminary trial on human volunteers.
    Jones RJ; Roe EA; Lowbury EJ; Miler JJ; Spilsbury JF
    J Hyg (Lond); 1976 Jun; 76(3):429-39. PubMed ID: 819576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The immunological response in volunteer donors immunized with a Pseudomonas vaccine].
    Makarenko TA; Balaian SS; Sergienko AI; Stanislavskiĭ ES; Edvabnaia LS; Abramova IA; Krokhina MA; Rusanov VM
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Nov; (11):39-41. PubMed ID: 1811387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.